Opinion

Video

Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.

Video content above is prompted by the following questions:

  • A subcutaneous form of ocrelizumab may come to market later this year. How will you incorporate this into your treatment algorithms?
  • Will payers evaluate coverage decisions for this therapy differently than the intravenous form?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
2 experts in this video
2 experts in this video
A panel of 3 experts on multiple sclerosis
A panel of 3 experts on multiple sclerosis
A panel of 3 experts on multiple sclerosis
A panel of 3 experts on multiple sclerosis
A panel of 3 experts on multiple sclerosis
A panel of 3 experts on multiple sclerosis
A panel of 3 experts on multiple sclerosis
3 KOLs in this program
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo